

# ***IVUS MLA Criteria and FFR: Left Main and Non- Left Main***

**Soo-Jin Kang, MD., PhD.**

Department of Cardiology, University of Ulsan College of Medicine  
Asan Medical Center, Seoul, Korea

# Disclosure Statement of Financial Interest

I, Soo-Jin Kang DO NOT have a financial interest /arrangement or affiliation with one or more organizations that could be perceived as a real or apparent conflict of interest in the context of the subject of this presentation


# Meta-analysis of 11 Clinical Trials

1759 patients with 1953 lesions


In Non-LM Lesions  
Weighted **MLA 2.61** mm<sup>2</sup>  
To predict FFR <0.80

Pooled sensitivity **79%**  
Pooled specificity **65%**


*Nascimento et al. Catheter  
Cardiovasc Interv 2013 (in press)*




	N	FFR	RLA	MLA	AUC	Sens	Spec	PPV	NPV	Accu
<b>Takaki</b> (1999 Circ)	51	0.75	9.3	<b>3.0</b>	—	83%	92%	—	—	—
<b>Briguori</b> (2001 AJC)	53	0.75	7.8	<b>4.0</b>	—	92%	56%	38%	96%	<b>64%</b>
<b>Ben-Dor</b> (2012 *)	205	0.80	8.6	<b>3.09</b>	0.73	69%	72%	—	—	<b>70%</b>
<b>Kang</b> (2011 Circ int)	236	0.80	7.6	<b>2.4</b>	0.80	90%	60%	37%	96%	<b>68%</b>
<b>Kang</b> (2012 AJC)	784	0.80	8.2	<b>2.4</b>	0.77	84%	63%	48%	90%	<b>69%</b>
<b>Koo</b> (2011 JACC int)	267	0.80	6.8	<b>2.75</b>	0.81	69%	65%	27%	81%	<b>67%</b>
<b>Gonzalo</b> (2012 JACC)	47	0.80	7.1	<b>2.36</b> IVUS	0.63	67%	65%	67%	65%	<b>66%</b>
<b>Gonzalo</b> (2012 JACC)	61	0.80	7.1	<b>1.95</b> OCT	0.70	82%	63%	66%	80%	<b>72%</b>

**A. RLD <2.75mm (n=193)**


Sensitivity 64% Specificity 69%

**B. RLD 2.75–3.5mm (n=456)**


Sensitivity 80% Specificity 68%

**C. RLD >3.5mm (n=166)**


Sensitivity 89% Specificity 65%

**D. Proximal (n=298)**


Sensitivity 78% Specificity 68%

**E. Mid (n=417)**


Sensitivity 84% Specificity 65%

**F. Distal (n=100)**


Sensitivity 78% Specificity 70%

**G. Proximal LAD (n=188)**

Sensitivity 79% Specificity 70%

**H. Mid-LAD (n=334)**

Sensitivity 85% Specificity 61%

**I. Distal LAD (n=30)**


Sensitivity 82% Specificity 90%

# Subgroup-specific MLA, accuracies <70-75%

*Kang et al. Am J Cardiol 2012;109:947-5*

544 intermediate lesions assessed in 516 pts from 24 centers  
FFR  $\leq 0.80$  in 169/544 lesions (31.1%) and 167/516 pts (32.4%)

	N	MLA cutoff	C-statistic	Accuracy
<b>All lesions</b>	544	2.9 mm <sup>2</sup>	0.66	66.0%
LAD	296	2.9 mm <sup>2</sup>	0.64	63.5%
LCX	110	2.4 mm <sup>2</sup>	0.72	77.3%
RCA	138	2.8 mm <sup>2</sup>	0.75	77.5%
Proximal	259	3.0 mm <sup>2</sup>	0.76	74.9%
Mid	195	2.6 mm <sup>2</sup>	0.63	65.6%
Distal	90	3.0 mm <sup>2</sup>	0.63	51.1%
RVD <3.0 mm	322	2.6 mm <sup>2</sup>	0.65	66.1%
RVD $\geq 3.0$ mm	219	3.0 mm <sup>2</sup>	0.71	72.6%
Length $\leq 12.3$ mm	272	3.0 mm <sup>2</sup>	0.67	64.7%
Length >12.3 mm	269	2.8 mm <sup>2</sup>	0.69	68.8%






	Beta	p-value	Adjusted OR	95% CI
<b><i>MLA &lt; 2.4 but FFR ≥ 0.8 “Mismatch”</i></b>				
Women	0.371	0.048	1.450	1.003 – 2.095
LAD location	-0.406	0.027	0.666	0.465 – 0.954
Reference lumen $\varnothing$	-1.209	<0.001	0.298	0.204 – 0.437
Distal segment	0.704	0.002	2.021	1.293 – 3.159
<b><i>MLA ≥ 2.4 but FFR &lt; 0.8 “Rev-mismatch”</i></b>				
Age	-0.062	<0.001	0.940	0.909 – 0.972
LAD location	0.813	0.071	2.256	0.932 – 5.460
Plaque rupture	2.410	<0.001	11.138	4.886 – 25.39

# Cut-off for Predicting LM FFR<0.75

## LM MLA 6.0mm<sup>2</sup>

- Sum of lumen areas of two daughter vessels (Each of LAD and LCX should be 4.0mm<sup>2</sup>)= 150% of the parent LM
- Murray's Law ( $LM r^3 = LAD r^3 + LCX r^3$ )




*Jasti et al. Circulation 2004;110:2831-6*



# New LM MLA 4.5mm<sup>2</sup>

Matched with FFR <0.80  
Ostial and Shaft LM Disease (N=112)




Sensitivity	79%
Specificity	80%
PPV	83%
NPV	76%

*Park SJ et al. JACC Interv 2014;7:868-74*

# Geometric Abstraction

Old MLA cut-off  $6.0\text{mm}^2$  was obtained from *Murray's law* considering an **MLA  $4.0\text{mm}^2$**  as ischemic threshold of both LAD and LCX

**LM  $6.0\text{mm}^2$**



LAD	LCX	LM (Murray's)
<b>4.0</b>	<b>4.0</b>	<b>6.35</b>
4.0	3.9	6.27
4.0	3.8	6.19
4.0	3.7	6.11
4.0	3.6	6.04
4.0	3.5	5.96

*De La Torre Hernandez et al. JACC 2011;58:351-8*


*Jasti et al. Circulation 2004;110:2831-6*

# False Assumption...

## The used cut-off 4.0mm<sup>2</sup> is too Big!


LAD	LCX	LM (Murray's)
3.0	3.0	4.76
3.0	2.9	4.68
3.0	2.8	4.60
<b>3.0</b>	<b>2.7</b>	<b>4.53</b>
3.0	2.6	4.45
3.0	2.5	4.37

Expected LM MLA



# In-vivo Validation

Jasti's data (n=55)




**MLA 6.0mm<sup>2</sup>**

**LM MLA (mm<sup>2</sup>)**

*Jasti et al. Circulation 2004;110:2831-6*


# AMC New Data (n=112)



**4.5 mm<sup>2</sup>**

**LM MLA (mm<sup>2</sup>)**

# AMC New Data (n=112)



- **Old data (MLA 6.0mm<sup>2</sup>)** included downstream SB disease, and 32 of 55 (58%) were distal LM lesions that usually extend to the SB ostia
- **Recent data (MLA 4.5mm<sup>2</sup>)** evaluated only pure LM lesions, which more reliably assessed the impact of LM-MLA on functional significance

**TABLE 1. Baseline Clinical, Angiographic, and IVUS Characteristics of Patients (n=55)**

Age, y	62±11
Diabetes mellitus, n	20
Hypertension, n	50
Smoking, n	39
Prior bypass surgery, n	13
Ostial LM stenosis, n	20
Mid-LM stenosis, n	3
Distal LM stenosis, n	32

# Ethnic Difference in LMCA Morphology

	Asian	White	p
No.	99	99	
Age, years	68±9	68±10	0.80
Men	77 (78%)	72 (73%)	0.41
BSA, m <sup>2</sup>	1.7±0.1	1.9±0.2	<0.001
BMI, kg/m <sup>2</sup>	24±3	28±4	<0.001
MLA, mm <sup>2</sup>	5.2±1.8	6.2±1.4	<0.001
Plaque burden, %	58 ±0	49±12	<0.001
<b>Normalized EEM,mm<sup>2</sup></b>	<b>20.7±4.5</b>	<b>19.3±4.2</b>	<b>0.024</b>
Normalized lumen,mm <sup>2</sup>	8.6±2.6	9.7±2.7	<0.001

The ethnic difference poorly supported the relevance of using 6.0mm<sup>2</sup>

*Rusinova et al. Am J Cardiol 2013;111:979-8*



# ***Independent Factors of LM FFR<0.80***

	<b>Odds ratio</b>	<b>95% CI</b>	<b>p</b>
<b><i>Model 1</i></b>			
Plaque rupture	4.47	1.35 – 14.8	0.014
BMI, kg/m <sup>2</sup>	1.19	1.00 – 1.41	0.05
Age, yrs	0.95	0.90 – 1.00	0.031
MLA, mm <sup>2</sup>	0.37	0.25 – 0.56	<0.001
<b><i>Model 2</i></b> including Echo-LV mass			
LV mass, g	1.01	1.00 – 1.03	0.03
Age, yrs	0.94	0.90 – 0.99	0.021
MLA, mm <sup>2</sup>	0.34	0.21 – 0.54	<0.001

*The suboptimal accuracy of LM-MLA is not surprising*

*Park SJ et al. JACC Interv 2014;7:868–74*

# ***Conclusions***

- In non-LM lesions, use of IVUS-MLA is not recommended for decision making to treat or not
- In pure LM lesions, IVUS-MLA  $4.5\text{mm}^2$  may be alternatively used to assess ischemia
- FFR still remains as the gold standard